Overview
- Defense Secretary Pete Hegseth announced a plan on July 15 to screen service members 30 and older for low testosterone and offer voluntary testosterone replacement therapy to those with low results.
- U.S. District Judge Ana Reyes took judicial notice of Hegseth’s announcement and ordered the parties to explain medical, logistical and cost similarities and differences between TRT for cisgender troops and masculinizing hormone care for transgender men.
- The court set an accelerated schedule with key deadlines including an Aug. 7 window for targeted submissions and a two-week trial slated to begin Jan. 4, 2027.
- Medical experts and opinion pieces warn that population-level testosterone screening departs from clinical norms, risks fertility loss, elevated red blood counts, clotting and behavioral effects, and lacks published diagnostic thresholds or monitoring plans.
- The judge’s inquiry could undercut the administration’s readiness and cost arguments used to justify the transgender ban, and the case now proceeds with certified class status that could affect current and prospective transgender service members.